Jun 10, 2022 / 02:30AM GMT
Patrick Nelson - ReachCapital Pty Ltd - CEO/MD
Good afternoon everyone and welcome to Prescient Therapeutics special investor briefing on their newly unveiled cell therapy enhancement platform CellPryme. My name is Patrick Nelson, MD of reach and I'll be hosting and facilitating today's webcast but more importantly we're joined by Prescient's MD and CEO
Steven Yutomi-Clarke and Senior Vice President of Scientific Affairs Dr. Rebecca Lim. Thank you for joining us today. In today's session Steven and Rebecca will provide an overview of Prescient's new platform for enhancing cell therapies or CellPryme and how it complements their existing next-gen CAR-T platform OmniCAR.
Now to stay up to date on Prescient's news type PTX which is the code they trade on the ASX into the chat box at any time during the presentation and we'll make sure that you'll get the rest of investor updates. We expect the session to run for approximately 30 minutes and there will be a Q&A session at the very end. If you'd like to ask a question at any time, simply type it into the question box and
Prescient Therapeutics Ltd Investor Briefing Transcript
Mar 29, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers